At a glance

From the latest edition of each brief.

Biotech & Pharma Intelligence

Two pan-RAS drugs showed pancreatic cancer data, both single-arm. Actinogen’s Alzheimer’s trial missed. · No. 052 · · About 4 min read

Erasca reports confirmed responses in 44% of 25 previously treated pancreatic cancer patients; Revolution Medicines reports 60.7% first line with chemotherapy. Stocks fell again on Thursday, and the VIX rose to 28.44.

XBI · 11.19
1D −0.6% · 1W −4.7% YTD +18.2%
144.12
IBB · 11.19
1D −0.8% · 1W −4.6% YTD +20.7%
203.72
UST 10-YEAR
11.19 · FROM 5.07% ON 11.18 2Y 4.76% · 2S10S +28BP
5.04%
US BIOTECH IPOS YTD
~$8.2B RAISED MIND CLUB TALLY · 11.20
30

Market figures as of the 11.19 close: XBI and IBB closes from Robinhood market data; Treasury yields from the U.S. Treasury daily par yield curve (11.19 and 11.18); IPO count and proceeds from the Mind Club financing tally (US sheet, IPOs of $5M or more, 11.20). SPY, IWM, fed funds and the VIX print in 01 Markets & outlook. Facts only, not a view on any security.

Verification at a glance

CLAIM CHECK
2 match · 2 partial · 1 open
5
CALENDAR DATES
confirmed at the source
18/22
REGISTRY WATCH
trials · 0 changes · full table in 14B
70
OPEN CALLS
none resolved today · see 15
3
CORRECTIONS
none new · see 16
17

The five-minute readThree that matter · one date · one open question

#What happenedSo what · our analysisPriority · sourcesPage
01Erasca’s pan-RAS pill ERAS-0015 drew confirmed responses in 44% of 25 previously treated pancreatic cancer patients at 32 mg, its chosen dose. The Phase 1 trial has no control group, and response rate is a secondary endpoint.Single-arm, early and company-reported, so it cannot show benefit over other treatment. Erasca plans a first-line pancreatic Phase 3 in the first half of 2027.Must read CoReg08
02Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer. In 61 patients, 60.7% had a confirmed response and median progression-free survival was 12.8 months.Another single-arm result. The randomized test against chemotherapy alone, RASolute 303, has not read out.Must read CoReg08
03Actinogen’s pivotal trial of Xanamem in Alzheimer’s disease missed its primary endpoint. The benefit on CDR-SB at week 36 was 0.10 points versus placebo, p = 0.65.The company points to a prespecified subgroup of older patients, but a subgroup after a missed primary is a reason for a new trial, not proof.Must read CoReg09
+Also today. 04 Regeneron’s Livsayis (cemdisiran), an RNAi drug from Alnylam, was approved for generalized myasthenia gravis. 05 AbbVie took an option to license AND-gated bispecifics from DISCO, with $40M upfront; Bloomberg reports Sanofi is weighing a bid for Insmed.09
DATEOne date to hold. Fri 11.27: FDA goal date for BridgeBio’s BBP-418 in limb-girdle muscular dystrophy 2I/R9, per BridgeBio. More in 14.18
OPENThe open question. Does adding a pan-RAS drug to first-line chemotherapy help patients live longer? Both of today’s RAS results are single-arm; RASolute 303, randomized against chemotherapy alone with survival as a co-primary, is designed to test it for daraxonrasib; primary completion is estimated for 04.2028.17

HOW TO READ THIS BRIEF

Must readunderstand today. Know itsecondary. Scanawareness only. Verified a primary source was checked, Claim a company statement, Analysis our interpretation, Forecast a dated judgment with odds. Red boxes are the red team. Source badges: Reg trial registry Gov agency or government Peer peer-reviewed journal Pre preprint Co company or organizer release or filing Data curated database Press journalism. Claim Check verdicts compare a headline with the registered protocol: MatchPartialMismatchOpen. A verdict says what differs, never why.

Reading priority index

  • Must readERAS-0015 in pancreatic cancer · Daraxonrasib first line · Xanamem misses · Claim Check · Target Evidence Card
  • Know itLivsayis approval · AbbVie and DISCO, Sanofi and Insmed · Policy & regulatory watch · Verified Catalyst Calendar
  • ScanBright spot · Registry Watch · Public Calls Ledger

AI & Technology Intelligence

The AI sell-off widens: the S&P 500 closes in correction as chip stocks fall about 10% · No. 052 · · About 4 min read

The S&P 500 fell 3.70% for a seventh straight loss and the Nasdaq 100 fell 5.61%. Nvidia, AMD, Micron and Arm each fell more than 13% in their last regular-session trades. Anthropic closed its IPO with about $119.5 billion in combined gross proceeds, and its shares fell 8.98% on their first full day, still above the $83 offer price.

QQQ · 11.20
DAY -5.43% NASDAQ 100 PROXY
610.04
SOXX (SEMIS)
DAY -10.61% SMH -10.66%
123.31
ARM
DAY -13.98% BIGGEST AI MOVER
152.40
AI ROUNDS ≥$100M
WINDOW · 1 ROUND TALLY NOT RE-RUN
$26.0B

Every index, chip stock and hyperscaler, and the 10-year, print in 01 Markets & outlook. The drivers are weighed in 04S.

Verification at a glance

CLAIM CHECK
2 match · 1 partial · 3 open
6
CALENDAR DATES
confirmed at the source
10/12
SOURCE WATCH
not re-run tonight · carried
0/30
OPEN CALLS
no change tonight
8
CORRECTIONS
log total; none new tonight
3

The five-minute readThree that matter · one to use · one open question

#What happenedSo what · our analysisPriority · sourcesPage
01The S&P 500 closes in correction. The S&P 500 fell 3.70% to 6,910.39, 11.62% below its 10.06 record close. The Nasdaq 100 fell 5.61% and the VIX closed at 35.89.The selling was heaviest in chips and memory, the companies closest to AI spending. Consumer staples and health care rose, per Reuters.Must read DataPress07
02Anthropic closes its IPO; the stock falls 8.98%. Anthropic says gross proceeds were about $93.5 billion from the offering and about $26.0 billion from a private placement. ANT’s last regular-session trade was $88.445.The stock is still above its $83 offer price. Some analysts say the deal may have pulled money from other tech; we found no fund-flow data showing it.Must read CoData07
03China chip sales come under new scrutiny. A House committee released license data on about 879,000 AI chips approved for China. A short seller, Hunterbrook, published claims about AMD’s firmware; AMD says the claims misrepresent its business.These are claims and disclosures, not findings. No regulator has acted against AMD or Nvidia on them.Must read GovPress08
+Special Coverage. Reading the sell-off, part two: seven possible drivers tested against the evidence, with a Red Team and a Blue Team. 04S. Also tonight. 04 Apple reportedly builds its own Mac agent. 05 Bright spot: OpenAI estimates its agents now finish about 46% of two-to-four-hour research tasks unaided.10
USEOne thing to use. If you build on Inception’s Mercury API, export your data by 12.28; Inception says the service stops after that date. Details in 08.14
OPENThe open question. Is this a repricing of AI spending, or forced selling that clears after options expiry? The week after expiry and the next prime brokerage data should help settle it.18

HOW TO READ THIS BRIEF

Must readunderstand tonight. Know itsecondary. Scanawareness only. Verified means a primary source was checked, Claim means a company or press statement, Analysis means our interpretation, Forecast means our odds, and Speculation means plausible but unverified. The red boxes are the red team: the strongest case against the implication just drawn. Source badges show what each item rests on: Reg a registry or filing Gov agency or government Peer peer-reviewed journal Pre preprint Data independent benchmark, market data or curated database Co company release, model card or pricing page Press journalism. Claim Check verdicts compare a headline with its primary document: MatchPartialMismatchOpen (no primary document found yet). A verdict says what differs, never why. Sandbox cards say where their evidence comes from: Documented testVendor demoProposedMind Club field test. Provenance, not a quality grade.

Reading priority index

  • Must readSpecial Coverage: reading the sell-off, part two · The correction · Anthropic’s close and second day · China chip scrutiny · Where this brief could be wrong
  • Know itApple’s reported Mac agent · Meta Muse testing report · Nvidia and Inception, as reported · Texas and Senate data center remarks
  • ScanGenie 4 in the Gemini API · DeepSeek round · Bloomington ordinance · Paper and model notes

Life Intelligence

Seven doors, a cookie and a committee · No. 002 · · About 2 min read

Greenland’s duel songs, a crossing button in Australia’s sound archive, a clothesline the palace turned down, and the 1796 cookies that rose on wood ash.

Season lens: November 8 brings Diwali and the distinct Sikh observance of Bandi Chhor Divas. Chhath Puja follows November 13 to 16, with prayers to the setting and rising sun. On November 11, children carry lanterns for Martinstag in parts of Europe. U.S. Thanksgiving falls November 26. Different traditions, different meanings, and quite a few reasons to gather. The north heads into winter; the south, into summer.

Scout cards this round
40
Doors in this edition
7
Scout cards that made the cut
1 in 5.7
Doors from outside the loop
6 of 7
Sources checked before print
53

This edition, briefly

  • 01 Signal: beef prices, leave and care, pumpkin butter, a Sumatra coffee lot. FOOD · FAM · BREW
  • 01 Bright spot: Abenaki voices, back from the archive. SOUND
  • 02.1 Greenland’s duel songs on old tape, and a singer setting them against synths. SOUND
  • 02.2 Australia put a pedestrian crossing button in its national sound archive. SOUND
  • 02.3 Shweshwe: South Africa’s indigo cloth, bleached into pattern. STYLE
  • 02.4 The clothesline offered to the Queen, and the note on the file. STYLE
  • 02.5 Dak’Art opens in Dakar’s old courthouse on November 19. CITY
  • 02.6 One pound every five weeks: coffee rationing and “Roosevelt coffee.” BREW
  • 02.7 Myth check: does getting cold give you a cold? BODY
  • 03 The Detour: how wood ash made a 1796 cookie rise. FOOD
  • 04 The Long Way Around: what UNESCO decides in Xiamen. EDIT · GAME · SOUND · FOOD
  • 05 Try: a free room in London, a lantern walk, a 1796 cookbook. CITY · FAM · EDIT
  • 06 Squared Away: a clothesline at the palace gates. PIXEL · WIT
  • 07 Play: five questions from this edition. GAME
  • 08 to 11 Where this brief could be wrong, the Public Calls Ledger (SPIEL Essen scored), Ask and corrections, and Sources. EDIT · RED TEAM

How to read this brief. Verified we opened the primary source and read the fact there. Claim someone with a stake, or a single secondary source, says it. Analysis our reading of the facts. Forecast a call we can be scored on. Taste a pick or a judgment, never evidence, always with its basis. Evidence insufficient we looked and couldn’t settle it. Every Door says how we found it. Cut ratio: scout cards printed as Doors, against cards scouted this round (7 of 40). Red boxes: the strongest case against us.